Janvier G, Freyburger G, Winnock S, Dugrais G, Boisseau M, Boissiéras P
Département d'Anesthésie-Réanimation I, Hôpital Pellegrin, Bordeaux, France.
Haemostasis. 1991;21(3):161-8. doi: 10.1159/000216221.
An open and prospective phase II trial assessing the action of a fixed dose of a low molecular weight heparin (enoxaparin), determined by the patient's weight, in the treatment of established deep vein thrombosis of the leg is hereby described. A series of 51 patients received a regimen of 1 mg.kg-1 or 105 anti-Xa IU.kg-1 s.c. every 12 h for a period of 12 days. Thromboses were categorized as postsurgical (28 cases) or medical (23 cases). There was a significant improvement in clinical signs (pain and edema) and phlebographic indices (Marder and Arnesen scores). The extent of vascular clearing was a 30% reduction in phlebographic scores between day 0 and day 12. Only 5 patients had an absence of improvement. Two of the 51 patients stopped the drug in the first week of treatment because of bleeding. There were no occurrences of thrombocytopenia, and the agent was well tolerated.
本文描述了一项开放性前瞻性II期试验，该试验评估根据患者体重确定的固定剂量低分子量肝素（依诺肝素）在治疗已确诊的下肢深静脉血栓形成中的作用。51例患者接受了每12小时皮下注射1mg.kg-1或105抗Xa IU.kg-1的方案，持续12天。血栓形成分为手术后（28例）或内科疾病所致（23例）。临床体征（疼痛和水肿）和静脉造影指标（Marder和Arnesen评分）有显著改善。血管清除程度为第0天至第12天静脉造影评分降低30%。只有5例患者无改善。51例患者中有2例在治疗的第一周因出血而停药。未发生血小板减少症，该药物耐受性良好。
